SEP 08, 2017 1:46 PM PDT

Lipoxin: A New Drug for Heart Attack Recovery

WRITTEN BY: Kara Marker

More than half of all heart attack patients die within five years of the event. This is a frightening statistic, but University of Alabama at Birmingham scientists are focused on making that number smaller and making lives longer. In their most recent study, published in the journal Scientific Reports, researchers boost post-heart attack healing with a molecule called lipoxin.

According to the American Heart Association, cardiovascular disease is the underlying cause of death for nearly 1 in every 3 deaths in the United States.

Lipoxins are right in the middle of the action when it comes to the immune system and have been used to treat inflammatory disorders, renal fibrosis, and even cancer because of it. They are known to be anti-inflammatory, making them the perfect candidate for reducing chronic inflammation following a heart attack.

The immune response following a heart attack isn’t inherently harmful. The first wave is an acute inflammatory response, where white blood cells flow into the heart tissues to remove dead cells and begin building scar tissue to replace them. After this, the immune response begins the healing process.

These two reactions are normal and healthy. But when the initial stage of acute inflammation turns into chronic inflammation, that’s a problem. Over time, excessive inflammation leads to swelling in the heart’s left ventricle, ultimately resulting in congestive heart failure and death.

But in the new University of Alabama at Birmingham study, researchers found that giving mice a form of lipoxin called 15-epimer lipoxin A4, also known as “aspirin-trigger lipoxin A4,” improved heart function after a heart attack by boosting activity during the healing phase but leaving the acute inflammation phase alone. With this effect, lipoxin reveals its therapeutic potential as a post-heart attack treatment.

The research team started by inducing heart attacks in mice models, followed by a treatment of lipoxin. To see how it worked to improve heart function, they took observed and measured the following:

  • Heart function and swelling in the lungs

  • Spleen and kidney function (These organs are also affected by the initial acute immune response during a heart attack)

  • Neutrophil clearance during the healing phase (Neutrophils are first-responders in the immune system)

  • Activation or inhibition of macrophage receptors (Macrophages engulf and digest dead and dying cells)

  • Changes in pro-resolving gene markers in the left ventricle, spleen and kidneys

  • Changes in interleukin levels (Certain interleukins indicate changes in the immune system)

  • Transition of fibroblasts into secretory myofibroblasts (Fibroblasts deposit collagen, contribution to scarring)

Analysis of these parameters led them to the final conclusion that lipoxin successfully boosts heart function after a heart attack. First, researchers saw an improved ejection fraction, a measurement of how much blood is pushed out of the heart when it contacts. The better the ejection fraction, the more oxygenated blood is sent out into the body to provide tissues with oxygen and nutrients.

In addition, researchers saw active receptors on reparative macrophages and inhibited receptors on inflammatory macrophages. Lipoxin increased the number of neutrophils pushing their way into the heart during acute inflammation, and it promoted the clearance of neutrophils and reparative macrophages during the healing phase.

All things considered, lipoxin has a powerful and beneficial effect on the heart at a time when recovery is extremely vital, for the short-term and for the long-term.

Sources: MayoClinic, Journal of Inflammatory Research, University of Alabama at Birmingham

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 24, 2021
Genetics & Genomics
A Potential New, Less Costly Treatment for Pompe Disease
AUG 24, 2021
A Potential New, Less Costly Treatment for Pompe Disease
Some rare genetic disorders impair a critical molecule that has to be replaced, or serious disease or disability will oc ...
SEP 02, 2021
Cancer
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
SEP 02, 2021
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
High cholesterol is associated with an increased risk of several types of cancer, and cancer patients with high choleste ...
AUG 30, 2021
Microbiology
Do Farmed Carnivores Promote Zoonotic Disease?
AUG 30, 2021
Do Farmed Carnivores Promote Zoonotic Disease?
Researchers have found that the immune systems of some carnivorous animals appear to be defective; they don't express a ...
AUG 31, 2021
Coronavirus
Researchers Use Newer Approach to Analyze Long Haul COVID-19 and Post Traumatic Stress Symptoms
AUG 31, 2021
Researchers Use Newer Approach to Analyze Long Haul COVID-19 and Post Traumatic Stress Symptoms
fMRI of some COVID-19 survivors suffering from posttraumatic stress symptoms reveal altered functional brain connectivit ...
SEP 06, 2021
Genetics & Genomics
How a Genetic Mutation Could Lead to Leaky Gut
SEP 06, 2021
How a Genetic Mutation Could Lead to Leaky Gut
In our gut, there is a vast community of microorganisms. It's crucial that they stay there in the gastrointestinal tract ...
SEP 13, 2021
Cancer
Fat Loss can Predict Gastric Cancer Survival
SEP 13, 2021
Fat Loss can Predict Gastric Cancer Survival
Cancer cachexia is a metabolic disorder in cancer patients experiencing uncontrolled weight loss.  While cancer cac ...
Loading Comments...